Cambridge, Massachusetts, United StatesFounded 202021+ employeesPrivate
$37.4M raisedSeries A· last: series a (May 2024)· 5 rounds
Nabla Bio is building an end-to-end antibody creation platform. Nabla Bio is applying natural language processing algorithms to amino acids generating a predictive “biophysical fingerprint” for 1 million antibodies in a single step.
Founders
Open Positions at Nabla Bio (14 Jobs)
14 open · 5 remote · 3 filled
